Figure 1.
Adverse clinical outcomes associated with double expressor status. Association of double expression of MYC (>40%) and BCL2 (>50%) with PFS and OS in the entire cohort (A-B) and in the MATRix-treated subgroup (C-D).
Adverse clinical outcomes associated with double expressor status. Association of double expression of MYC (>40%) and BCL2 (>50%) with PFS and OS in the entire cohort (A-B) and in the MATRix-treated subgroup (C-D).
